Texas 2023 - 88th Regular

Texas House Bill HB25 Latest Draft

Bill / Enrolled Version Filed 05/23/2023

Download
.pdf .doc .html
                            H.B. No. 25


 AN ACT
 relating to wholesale importation of prescription drugs in this
 state; authorizing a fee.
 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:
 SECTION 1.  This Act may be cited as the Wholesale
 Prescription Drug Importation Act.
 SECTION 2.  Subtitle A, Title 6, Health and Safety Code, is
 amended by adding Chapter 444 to read as follows:
 CHAPTER 444. WHOLESALE PRESCRIPTION DRUG IMPORTATION PROGRAM
 Sec. 444.001.  DEFINITIONS. In this chapter:
 (1)  "Canadian supplier" means a manufacturer,
 wholesale distributor, or pharmacy that is appropriately licensed
 or permitted under Canadian federal or provincial laws and rules to
 manufacture, distribute, or dispense prescription drugs.
 (2)  "Commission" means the Health and Human Services
 Commission.
 (3)  "Prescription drug wholesaler" means a person
 licensed as a wholesale distributor under Subchapter N, Chapter
 431, that contracts with this state to import prescription drugs
 under the program.
 (4)  "Program" means the wholesale prescription drug
 importation program established under this chapter.
 Sec. 444.002.  ESTABLISHMENT OF WHOLESALE PRESCRIPTION DRUG
 IMPORTATION PROGRAM. (a) The commission shall establish the
 wholesale prescription drug importation program to provide lower
 cost prescription drugs available outside of the United States to
 consumers in this state at the lower cost.
 (b)  The commission shall implement the program by:
 (1)  contracting with one or more prescription drug
 wholesalers and Canadian suppliers to import prescription drugs and
 provide prescription drug cost savings to consumers in this state;
 (2)  developing a registration process for health
 benefit plan issuers, health care providers, and pharmacies to
 obtain and dispense prescription drugs imported under the program;
 (3)  developing a list of prescription drugs, including
 the prices of those drugs, that meet the requirements of Section
 444.003 and publishing the list on the commission's Internet
 website;
 (4)  establishing an outreach and marketing plan to
 generate program awareness;
 (5)  establishing and administering a telephone call
 center or electronic portal to provide information about the
 program;
 (6)  ensuring the program and the prescription drug
 wholesalers that contract with this state under Subdivision (1)
 comply with the tracking, tracing, verification, and
 identification requirements of 21 U.S.C. Section 360eee-1;
 (7)  prohibiting the distribution, dispensing, or sale
 of prescription drugs imported under this chapter outside the
 boundaries of this state; and
 (8)  performing any other duties the executive
 commissioner determines necessary to implement the program.
 (c)  The commission shall ensure that the program meets the
 requirements of 21 U.S.C. Section 384.
 (d)  In developing the program, the commission may consult
 with interested parties.
 Sec. 444.003.  ELIGIBLE PRESCRIPTION DRUGS. A prescription
 drug may be imported into this state under the program only if the
 drug:
 (1)  meets the United States Food and Drug
 Administration's standards related to prescription drug safety,
 effectiveness, misbranding, and adulteration;
 (2)  does not violate any federal patent laws through
 its importation;
 (3)  is expected to generate cost savings for
 consumers; and
 (4)  is not:
 (A)  listed as a controlled substance under state
 or federal law;
 (B)  a biological product;
 (C)  an infused drug;
 (D)  an intravenously injected drug;
 (E)  a drug that is inhaled during surgery; or
 (F)  a parenteral drug.
 Sec. 444.004.  ANTICOMPETITIVE BEHAVIOR MONITORING. The
 commission, in consultation with the attorney general, shall
 identify and monitor any potential anticompetitive activities in
 industries affected by the program.
 Sec. 444.005.  PROGRAM FUNDING. In addition to money
 appropriated by the legislature, the commission may impose a fee on
 each prescription drug sold under the program or establish another
 funding method to administer the program.
 Sec. 444.006.  AUDIT PROCEDURES. The executive commissioner
 by rule shall develop procedures to effectively audit a
 prescription drug wholesaler participating in the program.
 Sec. 444.007.  ANNUAL REPORTING. Not later than December 1
 of each year, the commission shall submit a report to the governor
 and the legislature regarding the operation of the program during
 the preceding state fiscal year, including:
 (1)  which prescription drugs and Canadian suppliers
 are included in the program;
 (2)  the number of health benefit plan issuers, health
 care providers, and pharmacies participating in the program;
 (3)  the number of prescriptions dispensed through the
 program;
 (4)  the estimated cost savings to consumers, health
 plans, employers, and this state since the establishment of the
 program and during the preceding state fiscal year;
 (5)  information regarding the implementation of the
 audit procedures under Section 444.006; and
 (6)  any other information:
 (A)  the governor or the legislature requests; or
 (B)  the commission considers necessary.
 SECTION 3.  As soon as practicable after the effective date
 of this Act, the executive commissioner of the Health and Human
 Services Commission shall adopt any rules necessary to implement
 Chapter 444, Health and Safety Code, as added by this Act.
 SECTION 4.  If before implementing any provision of this Act
 a state agency determines that a waiver or authorization from a
 federal agency is necessary for implementation of that provision,
 the agency affected by the provision shall request the waiver or
 authorization and may delay implementing that provision until the
 waiver or authorization is granted.
 SECTION 5.  This Act takes effect September 1, 2023.
 ______________________________ ______________________________
 President of the Senate Speaker of the House
 I certify that H.B. No. 25 was passed by the House on April
 12, 2023, by the following vote:  Yeas 144, Nays 1, 2 present, not
 voting.
 ______________________________
 Chief Clerk of the House
 I certify that H.B. No. 25 was passed by the Senate on May 22,
 2023, by the following vote:  Yeas 31, Nays 0.
 ______________________________
 Secretary of the Senate
 APPROVED:  _____________________
 Date
 _____________________
 Governor